Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024
15 avr. 2024 08h00 HE
|
Akari Therapeutics Plc
BOSTON and LONDON, April 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today...
Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights
01 avr. 2024 06h30 HE
|
Akari Therapeutics Plc
BOSTON and LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
05 mars 2024 08h00 HE
|
Akari Therapeutics Plc
BOSTON and PLEASANTON, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and...
Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing
02 janv. 2024 08h00 HE
|
Akari Therapeutics Plc
BOSTON and LONDON, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
Akari Therapeutics to Present at Biotech Showcase 2024
14 déc. 2023 08h00 HE
|
Akari Therapeutics Plc
NEW YORK and BOSTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors
01 déc. 2023 08h00 HE
|
Akari Therapeutics Plc
NEW YORK and BOSTON, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference
16 nov. 2023 08h00 HE
|
Akari Therapeutics Plc
BOSTON and LONDON, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference
06 nov. 2023 08h00 HE
|
Akari Therapeutics Plc
BOSTON and LONDON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
Akari Therapeutics Reports First Half 2023 Financial Results and Highlights
29 sept. 2023 08h00 HE
|
Akari Therapeutics Plc
Akari’s priority pipeline programs remain on track to begin enrollment in the registrational nomacopan Phase 3 clinical trials in pediatric and adult HSCT-TMA and start PAS-nomacopan clinical trials...
Akari Therapeutics to Present at Emerging Growth Conference
27 sept. 2023 08h00 HE
|
Akari Therapeutics Plc
BOSTON and LONDON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...